Dinja Oosterhoff News Today : Breaking News, Live Updates & Top Stories | Vimarsana

First in human phase I clinical study using OMV as an adjuvant for intranasal vaccinationAvacc 10® intranasal booster vaccine induces a mucosal response and no adverse eventsData will be presented at the World Vaccine Conference on April 3rd 2024 in Washington, DC BILTHOVEN, The Netherlands, March 26, 2024 (GLOBE NEWSWIRE) -- Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced positive clinical data of a first in human (FIH)

Intravacc announces positive preclinical data for its SARS- CoV-2 nose spray vaccine Intranasal administration of OMV-Spike protected against challenge with SARS-CoV-2 Intranasal vaccine administration has significant advantages over injectables OMV technology is a powerful vaccine platform for future pandemics   Bilthoven, The Netherlands, 7 April 2021 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has obtained positive preclinical results for its SARS-CoV-2 Outer Membrane Vesicle (OMV) based recombinant Spik...

Share this article Share this article BILTHOVEN, Netherlands, April 7, 2021 /PRNewswire/ -- Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has obtained positive preclinical results for its SARS-CoV-2 Outer Membrane Vesicle (OMV) based recombinant Spike protein (rSp) candidate nose spray vaccine. For the preclinical study four groups of mice and four groups of hamsters received two intranasal immunizations on day one and day 21. One group of mice and hamsters received a vaccine based on OMV's mixed with rSp (CovOM...